Modular Medical Inc. (Modular Medical (MODD)) just hit a milestone that matters: real people are actually using its Pivot insulin pump. On Tuesday, the company announced that the first patients have finished onboarding and training and are now actively using the tubeless patch pump in their daily lives.

This is the moment when a medical device stops being a prototype and starts being a product. The Pivot pump has moved from development into active patient use, and Modular Medical is now collecting real-world data and feedback to refine the device and push for broader adoption.

"For the first time, patients are using Pivot to manage their insulin therapy, validating our vision of creating a simpler, more accessible pump solution for people who have historically remained on multiple daily injections," said Jeb Besser, CEO of Modular Medical. "This is only the beginning of our efforts to address this substantial market opportunity, and we look forward to gathering real-world data and feedback, as we seek to scale adoption and achieve long-term growth."

This news comes just a week after the company said the Pivot pump is now commercially available in the U.S., marking its transition to a commercial-stage medical device company. The path to this point included FDA 510(k) clearance in April, which gave the green light for the company to start selling the device.

The Pivot is a two-part tubeless patch pump with a removable 3 mL reservoir, a disposable battery, smartphone connectivity for bolus dosing and monitoring, and no tubes or constant wear. It's designed for people who have been stuck on multiple daily injections and want something simpler.

In April, Modular Medical also raised about $3.4 million through a registered direct offering of 750,000 shares at $4.50 per share, giving it some runway for the commercial push.

Looking ahead, Besser said the company is shifting focus to "rapid commercialization strategy, additional software enhancements, and European CE Mark progress in the second half of 2026." He added that they look forward to providing operational and adoption updates in the coming months.

As for the stock, Modular Medical shares were down 5.12% at $4.63 in premarket trading on Tuesday, according to market data. That's not unusual for a company at this stage — the market is watching to see if the real-world data translates into actual sales.